5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid | 919475-78-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid
• 英文别名: 5-(5-chloro-thiophen-2-yl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid；5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazol-3-carboxylic acid；3-(5-Chlorothiophen-2-yl)-2-(2,4-dichlorophenyl)-3,4-dihydropyrazole-5-carboxylic acid
• CAS: 919475-78-8
• 化学式: C₁₄H₉Cl₃N₂O₂S
• 分子量: 375.663
• InChiKey: JVQFUCDLDBHQEZ-UHFFFAOYSA-N

物化性质

• 熔点：
  82-84 °C(Solv: ligroine (8032-32-4))
• 沸点：
  539.9±60.0 °C(Predicted)
• 密度：
  1.66±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid 在 N,N-二甲基甲酰胺 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以74%的产率得到5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazol-3-carbonyl chloride
  参考文献：
  名称：

  Active substance combination for the treatment of diabetes

  摘要：

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，用于治疗糖尿病，包括该活性物质组合的药物、包括该活性物质组合的制药配方以及利用该活性物质组合制造药物的用途。

  公开号：

  EP1946778A1
• 作为产物：
  描述：

  5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  Diaryl Dihydropyrazole-3-carboxamides with Significant In Vivo Antiobesity Activity Related to CB1 Receptor Antagonism:  Synthesis, Biological Evaluation, and Molecular Modeling in the Homology Model

  摘要：

  A number of analogues of diaryl dihydropyrazole-3-carboxamides have been synthesized. Their activities were evaluated for appetite suppression and body weight reduction in animal models. Depending on the chemical modification of the selected dihydropyrazole scaffold, the lead compounds-the bisulfate salt,of (+/-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 26 and the bisulfate salt of (-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole3-carboxylic acid morpholin-4-ylamide 30-showed significant body weight reduction in vivo, which is attributed to their CB1 antagonistic activity and exhibited a favorable pharmacokinetic profile. The molecular modeling studies also showed interactions of two isomers of (+/-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4,5-dihydro- 1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 9 with CB I receptor in the homology model similar to those of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxarnide (rimonabant) 1 and 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-pheny1-4,5-dihydro-1H-pyrazole-1-carboxamidine (SLV-319) 2.

  DOI：

  10.1021/jm061490u

文献信息

• Substituted pyrazoline for preventing weight gain
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1946777A1

  公开（公告）日：2008-07-23

  The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，该药物以体重增加作为副作用而知名，包括所述活性物质组合的药物、包括所述活性物质组合的药物制剂、以及利用所述活性物质组合制造药物。
• Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1743894A1

  公开（公告）日：2007-01-17

  The present invention relates to heterocyclyl-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及杂环基取代的吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• WO2007/9690
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] HETEROCYCLYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS<br/>[FR] COMPOSES DE PYRAZOLINE A SUBSTITUTION HETEROCYCLYLE, PREPARATION ET UTILISATION DE CEUX-CI COMME MEDICAMENTS
  申请人：ESTEVE LABOR DR

  公开号：WO2007009690A1

  公开（公告）日：2007-01-25

  [EN] The present invention relates to heterocyclyl-substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
  [FR] L'invention concerne des composés de pyrazoline à substitution hétérocyclyle, des procédés de préparation de ceux-ci, des médicaments comprenant ces composés ainsi que l'utilisation de ceux-ci dans la préparation d'un médicament destiné au traitement d'êtres humains et d'animaux.
• Diaryl Dihydropyrazole-3-carboxamides with Significant In Vivo Antiobesity Activity Related to CB1 Receptor Antagonism:  Synthesis, Biological Evaluation, and Molecular Modeling in the Homology Model
  作者：Brijesh Kumar Srivastava,*、Amit Joharapurkar、Saurin Raval、Jayendra Z. Patel、Rina Soni、Preeti Raval、Archana Gite、Amitgiri Goswami、Nisha Sadhwani、Neha Gandhi、Harilal Patel、Bhupendra Mishra、Manish Solanki、Bipin Pandey、Mukul R. Jain、Pankaj R. Patel

  DOI：10.1021/jm061490u

  日期：2007.11.1

  A number of analogues of diaryl dihydropyrazole-3-carboxamides have been synthesized. Their activities were evaluated for appetite suppression and body weight reduction in animal models. Depending on the chemical modification of the selected dihydropyrazole scaffold, the lead compounds-the bisulfate salt,of (+/-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 26 and the bisulfate salt of (-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole3-carboxylic acid morpholin-4-ylamide 30-showed significant body weight reduction in vivo, which is attributed to their CB1 antagonistic activity and exhibited a favorable pharmacokinetic profile. The molecular modeling studies also showed interactions of two isomers of (+/-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4,5-dihydro- 1H-pyrazole-3-carboxylic acid morpholin-4-ylamide 9 with CB I receptor in the homology model similar to those of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxarnide (rimonabant) 1 and 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-pheny1-4,5-dihydro-1H-pyrazole-1-carboxamidine (SLV-319) 2.